Search PubMed⌕ Search

Biomedical subjects

A Pertzelan

Publications and source records attributed to A Pertzelan.

79 records · Page 5Linked to original sources

Two types of growth hormone rhythm in boys with constitutional short stature.

The relationship between temporal and quantitative changes in pulsatile growth hormone (GH) secretion and growth of constitutionally short children (CSS) was studied in 19 prepubertal boys and 4 with early adrenarche aged 7.8 to 14 years. Continuous plasma GH monitoring was performed at 30 minutes intervals during 24 hours. The data were analysed by single and serial best fit (BFT) cosinor analysis for rhythm parameters and the Pulsar peak detection program for determining pulsatile properties. The pulsatile patterns were expressed in mean GH concentration, area under the curve, mean pulse area and maximal pulse height but not in the number of pulses. Thirteen out of 23 patterns exhibited significant 24-h compatible rhythms. The studied cohort was divided into two groups, those who exhibited the 24-h circadian rhythm (CIR) and those who lacked it (NCIR). Ultradian 2.5-4 h rhythms were observed in all patients. The NCIR children were significantly shorter than the CIR group (p = 0.017). The CIR boys secreted a significantly higher (p = 0.01) amount of GH during the 24-h span, most of which was during sleep. Our data indicate that the magnitude of pulses rather than their number is responsible for the quantitative differences observed between the two groups of boys with CSS. It is suggested that a lack of 24-h rhythmicity and the associated reduced nocturnal pulsatility play a role in the manifestation of short stature.

Activity Cycles↗

Growth during and 2 years after stopping GH treatment in prepubertal children with idiopathic short stature.

Forty-six prepubertal children with idiopathic short stature (ISS), 39 boys and 7 girls, with a mean age of 7.4 +/- 1.8 (SD) years, and mean bone age of 4.5 +/- 1.5 years were treated by human growth hormone (GH) 0.1 U/kg/day s.c. for 30.5 +/- 16.2 months (M +/- SD) (2-5 years range) and were followed for 1-2 years after stopping GH. The mean net gain in height at the end of treatment was 1.03 +/- 0.6 SDS and the bone age SDS was accelerated by 0.95 +/- 1.05. Despite a transitory "catch-down" in growth velocity after stopping GH administration, there was a mean height gain at the end of 2 years follow-up of 0.87 SDS. Children who started treatment before age 6.5 benefited more than older ones. In conclusion, the gain in height observed in children with ISS by GH treatment was maintained during 2 years of follow-up after interruption of treatment. Even if this benefit is transitory and not permanent, it may help short children to achieve self-confidence and raise their physical performance at the critical period of school entry.

Age Determination by Skeleton↗